Kezar Life Sciences, Inc. (KZR) Stock Analysis

Kezar Life Sciences, Inc. (KZR) Healthcare & Pipeline Overview

Kezar Life Sciences, Inc. is a clinical-stage biotechnology firm specializing in small molecule therapeutics for immune-mediated diseases and cancer, with KZR-616 leading its pipeline in Phase 2 trials, positioning it within a competitive landscape of innovative drug developers.

What Is the Investment Thesis for KZR?

Kezar Life Sciences presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biotechnology companies. The primary value driver is KZR-616, currently in Phase 2 trials, with positive data readouts expected over the next 12-24 months potentially driving significant stock appreciation. Successful clinical trial outcomes and subsequent regulatory approvals would validate the company's immunoproteasome inhibition approach. However, the company's valuation is highly dependent on the success of KZR-616 and its other pipeline candidates. Failure to achieve positive clinical results or secure regulatory approvals would negatively impact the stock. With a market cap of $53.9M and a beta of 0.43, Kezar exhibits moderate volatility. Investors should carefully weigh the potential upside against the inherent risks of biotechnology investing.

Based on FMP financials and quantitative analysis

KZR Key Highlights

KZR-616 is in Phase 2 clinical trials for lupus nephritis, dermatomyositis, and polymyositis, targeting significant unmet medical needs.

• KZR-616 is also in Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis, expanding its potential application.
• KZR-261, a novel first-in-class protein secretion inhibitor, is in preclinical development, representing a potential future growth driver.
• The company has a market capitalization of $53.9M, reflecting its early-stage development profile.
• Kezar Life Sciences was founded in 2015, indicating a relatively young company with significant growth potential.

Who Are KZR's Competitors?

KZR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are KZR's Key Strengths?

Promising lead product candidate (KZR-616) in Phase 2 clinical trials.

• Novel approach to treating immune-mediated diseases and cancer.
• Experienced management team with expertise in drug development.

What Are KZR's Weaknesses?

Reliance on the success of KZR-616 and other pipeline candidates.

• Limited financial resources compared to larger pharmaceutical companies.
• High risk of clinical trial failure and regulatory setbacks.

What Could Drive KZR Stock Higher?

KZR catalyst: Data readouts from Phase 2 clinical trials of KZR-616 in lupus nephritis, dermatomyositis, and polymyositis.

• Initiation of clinical trials for KZR-261.
• Potential for strategic partnerships and collaborations.

What Are the Key Risks for KZR?

Financial-distress signal — its Altman Z-Score of 1.05 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-58.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Unfavorable clinical trial results for KZR-616 or other pipeline candidates.
• Regulatory delays or rejection of marketing applications.
• Competition from other companies developing therapies for immune-mediated diseases and cancer.
• Dependence on securing additional funding to support research and development activities.

What Are the Growth Opportunities for KZR?

• Expansion of KZR-616 into new indications: The success of KZR-616 in its current Phase 2 trials could pave the way for its expansion into other immune-mediated diseases. The market for autoimmune disease treatments is substantial, with a global market size estimated at billions of dollars. Positive clinical data and regulatory approvals could significantly increase Kezar's market opportunity and revenue potential.
• Advancement of KZR-261 into clinical development: KZR-261, a novel first-in-class protein secretion inhibitor, represents a potential breakthrough in treating various diseases. Moving KZR-261 into clinical trials would mark a significant milestone for Kezar, potentially attracting partnerships and further investment. The market for protein secretion inhibitors is nascent but promising, with potential applications in oncology and immunology.
• Strategic partnerships and collaborations: Kezar could pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. Collaborations can provide access to funding, expertise, and distribution networks, enhancing Kezar's ability to bring its therapies to market. The biotechnology industry is characterized by frequent collaborations, with companies leveraging each other's strengths to maximize their potential.
• Expansion of the pipeline through internal discovery and licensing: Kezar can expand its pipeline by identifying new drug targets and developing additional small molecule therapeutics. The company can also license promising compounds from other research institutions or biotechnology firms. A diversified pipeline reduces risk and increases the likelihood of bringing successful therapies to market. The biotechnology industry is constantly evolving, with new discoveries and technologies emerging regularly.
• Potential for acquisition by a larger pharmaceutical company: Given its innovative pipeline and promising clinical data, Kezar could be an attractive acquisition target for a larger pharmaceutical company seeking to expand its portfolio of immune-mediated disease and cancer therapies. Acquisitions are common in the biotechnology industry, with larger companies often acquiring smaller firms to gain access to their technologies and product candidates. An acquisition could provide Kezar's investors with a significant return on their investment.

What Are KZR's Competitive Advantages?

• Proprietary small molecule therapeutics with unique mechanisms of action.
• Patent protection for its product candidates.
• Expertise in immunoproteasome inhibition and protein secretion inhibition.

What Does KZR Do?

Kezar Life Sciences, Inc., founded in 2015 and based in South San Francisco, California, is a biotechnology company dedicated to the discovery and development of novel small molecule therapeutics. The company targets unmet needs in immune-mediated diseases and cancer, aiming to provide innovative treatment options for patients with limited alternatives. Kezar's lead product candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for lupus nephritis, dermatomyositis, and polymyositis. Additionally, KZR-616 is in Phase 1b clinical trials for systemic lupus erythematosus and lupus nephritis. Beyond KZR-616, Kezar is advancing a pipeline of preclinical products, including KZR-261, a novel first-in-class protein secretion inhibitor, and KZR-TBD for oncology and immunology applications. The company's research and development efforts are focused on creating differentiated therapies that address the underlying mechanisms of disease, with the goal of improving patient outcomes and quality of life. Kezar operates primarily in the United States, conducting its clinical trials and preclinical research within the country. The company's strategy involves identifying promising drug targets, developing proprietary small molecule compounds, and advancing these compounds through preclinical and clinical development stages. Kezar's success hinges on the positive outcomes of its clinical trials and the ability to secure regulatory approvals for its product candidates.

What Products and Services Does KZR Offer?

• Develop novel small molecule therapeutics.
• Target unmet needs in immune-mediated diseases.
• Target unmet needs in cancer.
• Conduct Phase 2 clinical trials for KZR-616 in lupus nephritis, dermatomyositis, and polymyositis.
• Conduct Phase 1b clinical trials for KZR-616 in systemic lupus erythematosus and lupus nephritis.
• Advance preclinical products, including KZR-261 and KZR-TBD.

How Does KZR Make Money?

• Discovery and development of proprietary small molecule therapeutics.
• Out-licensing or partnering with larger pharmaceutical companies for commercialization.
• Generating revenue through potential future sales of approved therapies.

What Industry Does KZR Operate In?

Kezar Life Sciences operates within the competitive biotechnology industry, characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The industry is driven by innovation, with companies constantly seeking to develop novel treatments for unmet medical needs. Kezar's focus on immune-mediated diseases and cancer places it within a growing market, as these conditions affect a large and increasing patient population. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms, all vying for market share. Kezar differentiates itself through its focus on small molecule therapeutics and its selective immunoproteasome inhibition approach.

Who Are KZR's Key Customers?

• Patients suffering from immune-mediated diseases.
• Patients suffering from cancer.
• Healthcare providers who treat these patients.

Kezar Life Sciences, Inc. (KZR) Valuation Context

Valued at $53.9M, KZR is classified as a micro-cap stock. Analyst price targets span from $5.00 to $21.00, with a consensus of $11.00. At the current price of $7.29, that implies approximately 51% upside potential.

KZR Revenue & Earnings Trend

In Mar 2026, KZR generated $0 in top-line revenue. The company recorded a net loss of $5.8M, with diluted EPS of $-0.78. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, KZR averaged $-1.54 in diluted EPS.

Company Profile

Kezar Life Sciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Christopher J. Kirk. KZR has traded publicly since 2018.

Return on equity for Kezar Life Sciences, Inc. stands at -58.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -66.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -78.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 24.46 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -84.5%, the inverse of the P/E and a quick read on earnings relative to price.

Kezar Life Sciences, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.05 places it in the distress zone, a signal of elevated financial risk.

Kezar Life Sciences, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 3.3% above estimates on average.

Wall Street analysts project Kezar Life Sciences, Inc. revenue of about $0 for fiscal 2026, with EPS near $-4.93.

Over the past six months, Kezar Life Sciences, Inc. insiders filed 30 SEC Form 4 transactions — 30 sales and 0 purchases. On net that is roughly 439K shares disposed (about $4.8M), a signal worth weighing alongside the fundamentals.

KZR Financials

KZR Latest News

Latest Kezar Life Sciences, Inc. Analysis

What Investors Ask About Kezar Life Sciences, Inc. (KZR) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources